Study design and population: casirivimab + imdevimab mAb prevention trial
Details of the casirivimab + imdevimab COV-2069 clinical trial for the prevention of COVID-19 are described elsewhereThe analysis set of participants without SARS-CoV-2 through day 8, included 829 and 801 participants in the mAb, and placebo arms, respectively (Supplementary Table The mAb and placebo arm participants display similar characteristics with a mean age of 42 years, 47% male, 86% white, mean body mass index (BMI) of 29, and 11% health care worker or first responder.